• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Rheumatoid Arthritis News / Efficacy of Leflunomide (Arava) in Treatment of Rheumatoid Arthritis

Efficacy of Leflunomide (Arava) in Treatment of Rheumatoid Arthritis

June 1, 1999 By Arthritis Center

In a recently published study (Lancet 353:259-266, 1999), Smolen et al reported on the results of a Phase III trial of leflunomide (AravaTM) for the treatment of rheumatoid arthritis (RA). 358 patients were randomly assigned to one of three treatments for 6 months: leflunomide (100 mg daily on days 1-3, then 20 mg daily); sulfasalazine (0.5g qd, titrated up to 2.0g qd); or placebo. The numbers of patients who responded to treatment, as assessed by the American College of Rheumatology 20% criteria, were significantly higher for the two treatment groups compared to the placebo group: leflunomide 55%, sulfasalazine 56%, placebo 29% (p=0.0001, leflunomide vs. placebo, sulfasalazine vs. placebo). Furthermore, radiologic bone progression, as measured by the Larsen score, was significantly reduced in the leflunomide and sulfasalazine groups compared to placebo. The most common adverse events reported by patients treated with leflunomide were diarrhea, nausea, rash, and alopecia. Two of the 133 patients treated with leflunomide were withdrawn from the study due to elevated liver function tests.

Editorial comment: These data confirm Phase II studies showing that leflunomide is efficacious in reducing the joint pain and swelling of RA. More importantly, they demonstrate that leflunomide is a disease modifying agent (i.e., it slows radiologic bone progression. Sulfasalazine also performed surprisingly well in this study (comparable to leflunomide). The ability to detect significant radiologic progression in just 6 months was another surprise. For more information about leflunomide and sulfasalazine.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy